Could the Biotech Investment National Security Act unintentionally benefit Europe?
The proposed BINSA (Biotech Investment National Security Act) aims to limit U.S. biotech exposure to China. But the legislation could have unintended consequences for global drug development.
The rise of “Eurowashing”
As restrictions on Chinese biotech evolve, European sponsors could become a pathway for Chinese-discovered therapies into global markets, potentially shifting investment and clinical development toward Europe.
Why Europe?
With strong clinical infrastructure, investigator networks and opportunities for efficient patient recruitment, Central and Eastern Europe could play an increasingly important role in global clinical development.
